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ABSTRACT
Next generation nanomedicine technologies are being developed to provide for continuous and
linked molecular diagnostics and therapeutics. Research is being performed to develop "sentinel
nanoparticles" which will seek out diseased (e.g. cancerous) cells, enter those living cells, and either
perform repairs or induce those cells to die through apoptosis. These nanoparticles are envisioned as
multifunctional "smart drug delivery systems".
The nanosystems are being developed as multilayered nanoparticles (nanocrystals, nanocapsules)
containing cell targeting molecules, intracellular re-targeting molecules, molecular biosensor
molecules, and drugs/enzymes/gene therapy. These "nanomedicine systems" are being constructed
to be autonomous, much like present-day vaccines, but will have sophisticated targeting, sensing,
and feedback control systems — much more sophisticated than conventional antibody-based
therapies. The fundamental concept ofnanomedicine is to not to just kill all aberrant cells by
surgery, radiation therapy, or chemotherapy. Rather it is to fix cells, when appropriate, one cell-at-a-
time, to preserve and re-build organ systems. When cells should not be fixed, such as in cases where
an improperly repaired cell might give rise to cancer cells, the nanomedical therapy would be to
induce apoptosis in those cells to eliminate them without the damaging bystander effects of the
inflammatory immune response system reacting to necrotic cells or those which have died from
trauma or injury.
The ultimate aim ofnanomedicine is to combine diagnostics and therapeutics into "real-time
medicine", using where possible in-vivo cytometry techniques for diagnostics and therapeutics. A
number ofindividual components ofthese multi-component nanoparticles are already working in in-
vitro and ex-vivo cell and tissue systems. Work has begun on construction of integrated nanomedical
systems.
Keywords: nanomedicine; nanoparticles, molecular biosensors, drug delivery, gene therapy; flow
cytometry; confocal microscopy; molecular diagnostics
1. INTRODUCTION
1.1 What is nanomedicine? Nanomedicine is a fundamentally different paradigm for medicine. It
is "nano" not only because it uses nanometer scaled tools, but also because it employs a cell-by-cell
regenerative and repair philosophy working at the single cell level rather than at the organ level.
Medicine has progressed from primitive surgery to detailed microsurgery on small regions of organs.
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The next step is nanomedicine which performs "nanosurgery" inside living single cells to either
repair those cells or to induce un-repairable cells to die by natural programmed cell death, avoiding
the effects of a inflammatory response by the body's immune system which in many cases can be
more severe than the original disease itself.
1.2 Some goals for nanomedicine: A goal ofmodem medicine is to provide earlier diagnostics so
that diseases can be treated when they are most treatable. Dramatic results have been achieved in a
number of diseases. However, diagnostics and therapeutics have not yet been combined in a
continuous system to not only diagnose, but also to treat, at the earliest possible stage — perhaps
before actual symptoms appear. The three conventional treatments for cancer are (1) surgical
removal ofthe tumor, (2) radiation therapy, and (3) chemotherapy. Nanomedicine attempts to make
smart decisions to either remove specific cells by induced apoptosis or repair them one cell-at-a-
time. Single cell treatments will be based on molecular biosensor information that controls
subsequent drug delivery to that single cell. Such a system would also need to be semi-autonomous,
with pre-determined decisions points for when a diagnosed condition warrants treatment. Clinical
decisions are usually much delayed by the negative potential side effects of that treatment,
particularly ifit turns out to be a misdiagnosis. Ifboth the accuracy oftreatment and the
minimization of unfavorable side effects and bystander effects could be brought to acceptable levels,
the consequences of faster autonomous treatments in continuous response to in-vivo molecular
diagnostics with slightly higher probabilities ofmisdiagnosis could be tolerated. In this paper we
discuss work still in the early stages of such a nanomedical system.
Conventional medicine is not readily available to much ofhumanity because it is labor-intensive.
Medical labor is sophisticated and expensive. Nanomedicine will be much more preventive,
combining very early diagnostics with initial therapeutics. In some ways it could resemble a smart,
multifunctional vaccine. It might also be less expensive because it will minimize use of expense
human experts for early diagnostics, and potentially could be mass produced and distributed.
1.3 Potential pitfalls of nanomedicine: We believe that it is important to discuss some of the
potential pitfalls, as well as the promise, in nanomedical systems for future drug-gene delivery. We
believe that the technology, while still in its infancy, has great promise to achieve these objectives.
But a realistic examination ofthe tradeoffs must also be assessed. For example, some nanosystems
very good for in-vitro work may have attributes that may preclude or limit their use in-vivo. Among
these are the potentially long-term cytotoxic effects of some nanomaterials. The cytotoxicity of some
nanomaterials in atom-by-atom or molecule-by-molecule nano self-assembly may prove to be very
different from those same materials in elemental form. Also, cytotoxicity is a far more complex
effect than simple cell killing, or even induction of apoptosis (programmed cell death). Ifthe gene
expression pattern is disturbed, those cells may not function, proliferate, or differentiate properly.
There is currently very little "cytotoxicity" data for nanomaterials in biological systems.
Nonetheless, it should be kept in mind that one ofthe main barriers remaining in modern
medicine is the effective and controlled delivery of drugs or genes to the targeted cells, with minimal
disturbance ofnon-targeted cells. The development ofhighly efficient and well-controlled delivery
of drugs or genes to cells would represent a significant advance to modern medicine. That fact
should be kept in mind in these still early days of nanomedical systems development. While there
are risks in the new systems, there are many problems of the existing old systems, too readily
accepted, because there have been no available alternatives. The proper development of
nanomedicine will require the balancing of risks with opportunities.
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1.4 Need for a nanoparticle gene delivery system: Existing gene delivery systems have a variety
oflimitations (De Smedt, Demeester, and Hennink 2000). Liposome based gene transfer methods
have relatively low transfection rates, are difficult to produce in a specific size range, can be
unstable in the blood stream, and are difficult to target to specific tissues (Dc Smedt, Demeester, and
Hennink 2000). Injection ofnaked DNA, RNA, and modified RNA directly into the blood stream
leads to clearance ofthe injected nucleic acids with minimal beneficial outcome (Sandberg et al.
2000). As such, there is currently a need for a gene delivery system which has minimal side effects
but high affectivity and efficiency. One such system could be that of the self-assembled
nanoparticles coated with targeting biomolecules (Lvov and Caruso 2001).
1.5 Application of nanomedicine to radiation damage in astronauts: In addition to describing
the general concepts ofnanomedicine, we show a particular application being developed for NASA
as part of their nanomedicine for astronauts program. New paradigms of any technology, including
nanomedicine, are often first developed for extreme environments andlor extreme circumstances.
Longer voyage space exploration qualifies on both fronts. For example, on a manned roundtrip
voyage to Mars and exploration on the surface of that planet, astronauts will encounter levels of
radiation that are impossible to shield. There will also be no hospitals with either diagnostic or
therapeutic treatments. The signal delays in Earth-Mars communications represents a major
challenge to telemedicine, and largely precludes procedures requiring real-time Earth control. Any
systems brought along must be small, low weight, intelligent, and autonomous. While there may be
large radiation damage effects, the most likely scenario is a series of fractionated radiation doses,
each of which is not necessarily a pivotal event, but whose accumulation can lead to further
downstream events such as organ injury or cancer. The strategy ofnanomedicine would be to try to
repair the radiation damage on a continuous basis using DNA repair enzymes in nanoparticle
systems targeted to cells likely to have experienced radiation as a counter-measure to more serious
radiation injury at the organ level.
2. MATERIALS AND METHODS
In the early developmental stages of this project we have used a variety of experimental model
systems which are very reproducible and testable, as described below. A basic strategy for a
nanomedical system applied to the problem of repairing radiation damage in astronauts on a
continuous basis is shown in the concept diagram of Figure 1.
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2.1 Nanoparticles: There are two general categories ofnanoparticles (with many variations)
currently being used for applications in in-vitro and in-vivo nanomedicine: (1) nanoparticle cores
with single or multilayered coatings, (2) hollow nanoparticle capsules without cores.
Nanoparticle cores materials vary greatly, the most common being made from gold, silica, or
semiconductor materials. Some are made from magnetic materials which can be useful for recovery
ofgene products within cells (Prow et al., 2004a). Many are now commercially available. Most of
these nanoparticles must be coated for two general purposes. First, some of them are not water-
soluble. To exist and to function in an in-vivo aqueous environment, some of these hydrophobic
materials must be marked with a layer ofhydrophilic molecules. Second, some ofthese materials are
cytotoxic to cells and tissues. Typically these are covered with lipophilic or other organic molecules
to provide a barrier between the cell and the core nanoparticle materials.
Hollow nanocapsules without cores come in a variety of sizes and materials. The simplest ones
consist of single or multiple layered liposomes, which are designed to fuse with the lipophilic
molecules of a cell membrane and then to spill the contents of the liposome into the interior of the
cell. More complex, layer-by-layer assembly nanocapsules are being made by some research groups.
These nanocapsules are self-assembling by alternating charged layers ofpolymers and similar
materials. In other work we have begun to develop nanosystems based on this concept (Prow et al.,
2004b). These nanocapsules are potentially biodegradable and may be less cytotoxic to biological
systems, although more detailed studies need to be conducted.
2.2 Nanoparticle targeting: Nanoparticle targeting can be accomplished in a variety ofways. But
the two most common, as shown in this paper, are use of antibodies (e.g. anti-CD95 antibody) bound
to the nanoparticle outer surface, or coating ofthe outer surface ofthe nanoparticles with molecules
that are the ligands for cellular receptors (e.g. mannose to target nanoparticles to liver cells which
have mannose receptors). While antibody targeting is very common for in-vitro applications, their
use in-vivo can be problematical since some ofthese targeting antibodies can illicit an immune
response from the human or animal. The mannose represents less of a problem in this regard because
the body already recognizes mannose and does not tend to mount an immune response against it.
In the particular application ofnanomedicine for astronauts we are using up-regulation and transport
ofthe CD95 molecule to the radiation (or oxidative stress) damaged cell. Amounts ofcell surface
CD95 vary in roughly a dose dependent maimer with radiation exposure (Sheard, 2001). So CD95
serves as the initial surrogate biomarker for radiation damage. We also have modeled radiation
dosed cells with two cell lines, one ofwhich expresses no CD95 (human MOLT-4 monocyte cell
line) and another cell line (BJAB) which expresses high quantities of cell surface CD95 . Once
inside, the nanoparticle system performs a secondary check for oxidative stress which is highly
correlated to radiation exposure using a biosensor sensitive to the presence ofreactive oxygen
species molecules. Since exact radiation exposure is difficult to control, we have used, in initial
studies, a chemical which produces the same oxidative stress as radiation but in an easily dosed
manner.
The other significant difference between in-vitro and in-vivo targeting is the great difference in
specificity required. Cells are usually not rare in-vitro, while targeted cells are almost always rare in-
vivo. Rare cell targeting presents considerable challenges in terms of specificity. Considering the
number ofpossible interactions in-vivo, the specificity of the overall targeting system must, in most
cases, be better than a million to one. No antibodies alone have this degree of specificity. To solve
this problem, Boolean combinations of antibodies must be chosen (for review, see Leary, 1994). The
good news is that these levels of specificity can be reached with antibody combinations of two
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positive biomarkers and one negative biomarker. The correct repertoire of these three biomarkers (or
cocktails ofbiomarkers as are frequently used for detection ofrare stem cells)
2.3 Cell entry facilitation: Most people do not realize that targeting ofnanoparticles to the cells of
interest for nanomedicine represents only the first part of a long and complex journey. A
nanoparticle is roughly one billionth the volume of a cell. So the interior of the cell represents
another new universe to the nanoparticle. The nanoparticle and/or its contents must get successfully
from the outside to the inside of a cell. How it enters the cell can control its subsequent fate. And
simply dumping the drug or gene contents of the nanoparticle into the interior of the cell, while
perhaps superior to dumping the drug or gene into the body for general circulation in the
bloodstream, still does not guarantee that the drug or gene gets to the intracellular site where it can
have therapeutic action. A further step of intracellular targeting is really required to be effective in
this process. We have used three entry facilitation methods: (1) arginine-repeat peptides, (2)
LipofectamineTM coatings to promote fusion ofnanoparticles with the cell membrane, and (3)
artificial tat-specific sequences, the entry and nuclear targeting molecule used by HIV-1.
2.4 Intracellular targeting: We have used a variety of specific amino acid localization sequences to
deliver and anchor delivery ofmolecules to three intracellular regions ofthe cell: (1) the
endoplasmic reticulum (ER), (2) the mitochondria, and (3) the nucleus. An important technology to
visualize and study the proper localization ofnanoparticles to their intracellular targets is confocal
microscopy. Since to allow for improved detection ofnanoparticles we used a Zeiss 510 META
confocal microscope with multispectral imaging capabilities which correct for color overlaps on a
pixel-by-pixel basis within each optical section. This spectral unmixing algorithm (Bearman et al.,
2002), referred to as "emission fingerprinting" provides for improved color deconvolution compared
to use ofconventional optical bandpass filters as shown in Figure 2.
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Figure 2: (A) The basic concept of emission fingerprinting is shown in schematic form. By
knowing directly or indirectly, all of the spectral contributions of each dye or probe plus the
autofluorescence spectrum of a cell, the colors can be "unmixed" on a pixel-by-pixel basis on
each plane of a multi-plane confocal image. (B) The algorithm essentially fits the overall color
curve using regions of each dye or component spectrum that are less contaminated with the
overlap of other colors. The resulting emission fingerprinting technique can be superior to the
use of conventional optical filters which still leave considerable optical overlap.
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2.5 Molecularbiosensing of the intracellular environment: Thus far we have explored both viral
biosensors and reactive oxygen species (ROS) biosensors. This paper will describe use of ROS
biosensors (Zhu and Fahi, 2000) coupled to an eGFP reporter gene which fluoresces green when
activated. Many biosensors share certain characteristics as shown in Figure 3.
2.6 Controlled drug-gene delivery: One ofthe ways we have tried to provide controlled drug/gene
delivery to living single cells, is to attach the gene therapeutic to the biosensor. That way the
therapeutic gene is only produced as long as the biosensor sees its target molecule. In this case we
are developing a transient gene therapy for DNA repair ofradiation-damaged DNA based on the
biosensing ofreactive oxygen species which has high correlation to radiation exposure.
An alternative treatment to repair is to accelerate the cell's natural "programmed cell death" or
apoptosis. This is particularly important in the case oftrying to repair radiation damaged cells in
astronauts. Ifthe cell is not repairable, we would prefer to have it die in a way that does not trigger
inflammatory responses ofthe immune system which can, in many diseases and injuries, be of
greater danger to the person than the disease or injury itself. In this application it is important to not
allow cancerous cells to arise from mutations produced by radiation damage.
3. DATA/RESULTS
3.1 Comparison of molecular immunochemical and nanoparticle targeting: While the two
processes are indeed quite different, fluorescent nanoparticle labeling can yield similar results to
those of conventional fluorescent antibody labeling techniques as shown in Figure 4. In this case we
used very large nanoparticles (approximately 500 nm diameter) in order to visualize the nanoparticle
labeling pattern. Improved concordance of nanoparticle labeling with molecular labeling is obtained
when nanoparticles are 100 nm or less diameters (data not shown, Prow thesis, 2004).
Taie1Eg to EiitiaI Cleavage domali sensitive Reporter molecule (e.g.
region of mierest to target molecule GFP or lucilerese)
For exançle. This biosensor can t designed to sense a target m The cel.
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Figure 3: Many
molecular biosensors
used for diagnostics
have targeting regions,
a cleavage domain that
is sensitive to enzymes
or proteases, and a
fluorescent reporter
molecule.
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Figure 4: Nanoparticles with
targeting molecules can label cells in
a manner that gives similar results to
conventional labeling with antibodies.
However, as the nanoparticles get
larger, they tend to bind in a
"quantized" manner that leads to
increasing discordance of results with
increasing nanoparticle size.
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Figure 5: (A) BJAB and MOLT-4 cell mixtures were labeled with 500 urn diameter
nanoparticles (small white spheres) and viewed by simultaneous phase contrast/fluorescence
microscopy using a Nikon Optiphot microscope. (B) To improve assay accuracy we pre-
labeled contaminating cell types (CD95 negative MOLT-4 cells) with CMAC (Molecular
Probes, Inc.) a blue fluorescence tracking dye (shown in this grey scale image as diffuse
grey). Nanoparticle (small white spheres in this grey level digital image) labeling showed
highly specific labeling ofthe CD95-positive BJAB cells with undetectable labeling of
CD95-neative MOLT-4 cells.
3.2 Measures of nanoparticle targeting efficiency and accuracy: To study nanoparticle binding
efficiency we performed phase contrast/fluorescence to allow viewing of cells that labeled or did not
label with nanoparticles (Figure 5A). Since this did not always allow for accurate identification of
the specific cells of interest, we used tracking dye labeling of the larger contaminating cells, not of
interest, to allow correct identification of all non-specific cell types in in-vitro experiments that
allowed modeling ofrare in-vivo targeting (Figure 5B).
3.3 Targeted delivery of nanocrystals: Streptavidin labeled nanocrystals were targeted to cells
labeled with biotinylated anti-CD95. The purpose ofthese experiments was to explore the entry
mechanisms of semiconductor nanocrystal nanoparticles. "Naked" nanoparticles (with no
biocoatings) did enter some cells non-specifically, showing that biocoatings were not only necessary
to target nanoparticles to the cells of interest but also necessary to prevent non-specific uptake.
Interestingly, Streptavidin coated nanocrystals when bound to the surface of cells labeled with
biotinylated anti-CD 95 monoclonal antibodies, not only targeted those cells in a highly efficient
manner, but also tended to internalize and track to the nuclei ofthose cells. HW tat sequences
proved highly efficient cell entry and nuclear localization molecules. Arginine rich amino acid
repeat peptides did not prove useful for nuclear localization, at least in our hands.
3.4 Application of nanomedical strategies to repair of radiation-damaged cells: To test the
feasibility of these approaches we conducted a series of in-vitro experiments. A antioxidants-
sensitive biosensor (Zhu and Fahl, 2000) was attached to DNA repair enzymes previously designed
and prepared in the lab of co-author RSL. When a cell undergoes oxidative stress it produces a series
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of molecules which will attach to the ARE biosensor which then can be used to drive the synthesis
of special DNA repair enzymes MutYIFpg designed by RSL (Figure 6).
(RcX:: SCflS(
This ARE biosensor, attached to a green fluorescent protein reporter sequences (eGFP), was
tested in cultures of T24 cells subjected to tert-butyihydroquinone (tBHQ), a chemical which
produces oxidative stress in cells in a manner similar to UV radiation, but which is more easily
dosed and controlled. The cell detects ROS and activates transcription factors which bind to specific
promoter regions. Transcription downstream of these response elements is then activated. The
construct used was constructed by Zhu and Fahl, 2000. This construct is composed of a number of
antioxidant response element (ARE) repeats followed by a minimal thymidine kinase promoter,
ahead of a EGFP reporter gene. The sensitivity of the biosensor is dramatically affected by the
number of ARE repeats, with four repeats giving optimal sensitivity (Zhu and Fahl, 2000). The
activity of this biosensor can be seen in T24 cells through the addition of 1 00 jiM tert-
butyihydroquinone, an inducer ofROS (Sigma-Aldrich Chemical, Inc., St. Louis, MO). T24 cells are
a human cell line derived from a transitional cell carcinoma that constitutively expresses CD95 on
the surface (Mizutani et al. 1997) (American Type Culture Collection, Manassas, VA). Cells
showing signs of oxidative stress were detected as green fluorescent positive cells as shown in
Figure 7
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Figure 6: During oxidative
stress a cell will produce
molecules which will binds to
the anti-oxidant response
element (ARE). The binding
ofthese molecules can be used
as a molecular biosensor to
drive the process of DNA
repair enzymes downstream in
the gene sequence construct.
Figure 7: Cells were
transiently transfected at
6O% confluence with either
ARE-GFP or TK-GFP. 24
hours later the cells were
treated with tert-
butylhydroquinone (tBHQ),
an ROS inducing agent, to
simulate the ROS effects of
radiation doses The cells
were examined every 12
hours post treatment. Weak
fluorescence (ARE-GFP)
shown in white was present
at hour 48 and photographs
were taken at hour 60.
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To test whether DNA repair enzymes could be introduced into cells damaged by actual UV radiation
to accelerate normal DNA repair mechanisms by activating a second repair pathway, not normally
expressed in human cells because one enzyme, a glycosylase, is absent in normal human cells
(Figure 8).
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Figure 8: (A) Assisted DNA repair concept for DNA damage to both nuclear and mitochondrial
DNA. (B) A specific strategy for assisting DNA repair ofUV damage in human cells.
This normally absent repair mechanism was activated by transfection of a glycosylase containing
gene sequence which also contained an eGFP reporter molecule. UV damage can occur in both
nuclear and mitochondrial DNA. Since many molecules introduced into a cell frequently track non-
specifically to the nucleus, we tested the ability of intracellular localization sequences to guide these
repair molecules to the mitochondria. In the absence of localization sequences, the repair molecules
did not appear to track to specific regions of the cell, as shown by the diffuse staining of Figure 9.
However when mitochondrial localization sequences were attached to the repair enzymes, they
tracked to the mitochondria as shown by confocal microscopy (Figures 9B and 9C). Either transient
or stable gene therapy was demonstrated.
In the present state of gene therapy concerns about patient
safety, our efforts are concentrated on the production of potentially
useful transient gene therapies using nanoparticle systems. To test
the actual effectiveness ofthese DNA repair enzymes inside living
uv "Assisted DNA Repair
Nanpahcks ernce
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Figure 9: (A) T4 transfected DNA repair enzyme with no
localization anchoring sequence (note diffuse fluorescence)
with transient expression (Wt-T4-PDG-GFP in CHO-XPG.
Transient expression. 1 OOx objective)
(B) T4 transfected DNA repair enzyme with mitochondrial
localization anchoring sequence, with transient expression
(MLS35-T4-PDG-GFP in CHO XPG. lOOx objective)
(C) T4 transfected DNA repair enzyme with mitochondrial
localization anchoring sequence, with stable expression
(MLS18-T4-PDG-GFP in hXPA. lOOx objective)
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cells, comet assays were performed in the laboratory of RSL. The "comet" assay (Tice, 2000) shows
the attempt of cell trying to repair its DNA strand breaks as a comet-like tail. When successful in
DNA repair, the comet tail is eliminated. Figure 10 clearly shows that repairable human cells can be
repaired in 6 hours by this assisted DNA repair transient gene therapy approach, as compared with a
required repair time of more than 24 hours using the usual DNA repair pathway functioning in
normal human cells. While far from proving efficacy in-vivo, these initial results show the promise
of this approach.
-
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Figure 10: A comet assay shows that DNA damage is successfully repaired at an accelerated
rate due to successfully activation of a second repair pathway in a transient gene therapy
approach to repairing DNA damage as it occurs.
4. CONCLUSIONS
These results, while still very preliminary, reveal some of the promise of nanotechnology for the
effective delivery oftherapeutic genes to individual living cells. As such it presents important
paradigm shifts in the delivery of medicine from a single choice of destruction of all affected cells to
one of selective repair of cells whenever possible and desirable and safe destruction through
apoptosis of un-repairable cells. It also shows how, in principle, autonomous nanoparticle systems
can be constructed to provide continuous molecular diagnostics/therapeutics at the single cell level.
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